- US FDA cleared IND for Phase 2 study of VT-7208 in chronic spontaneous urticaria.
- Company highlights ~$200M private placement extending cash runway into H2 2029.
- Pipeline expanded via research collaboration with Generian Pharmaceuticals.
?? Positive AI Sentiment (+6.5 / 10)